{"id":"NCT00105508","sponsor":"EMD Serono","briefTitle":"Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia","officialTitle":"A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09-30","primaryCompletion":"2006-02-28","completion":"2006-02-28","firstPosted":"2005-03-16","resultsPosted":"2018-07-26","lastUpdate":"2018-07-26"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease","Dyskinesia"],"interventions":[{"type":"DRUG","name":"Sarizotan","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sarizotan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).","primaryOutcome":{"measure":"Responder Rate Based on Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Sarizotan","deltaMin":30.4,"sd":null},{"arm":"Placebo","deltaMin":33.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["18175337"],"seeAlso":["https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001593-10/results"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":252},"commonTop":["Fall","Parkinsonism","Dyskinesia","Nausea","Depression"]}}